GASP-1 Peptide Biomarker Detection via 2-D HPLE Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker technologies fail to effectively detect early stage cancer due to low concentration and rapid turnover of cancer-associated peptides, and existing separation methods cannot distinguish serum albumin complexes, limiting the identification of useful biomarkers for early cancer detection and treatment.
Innovation Solution
The use of G-protein coupled receptor-associated sorting protein 1 (GASP-1) and its peptide fragments as biomarkers, detected through a modified 2-D High Performance Liquid Electrophoresis (2-D HPLE) method that separates albumin complexes on a PVDF membrane, allowing for the identification of cancer peptide motifs and their use in diagnostic tools and therapeutic targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional biomarker detection methods are used, then detection capability is limited, but early stage cancer detection sensitivity is insufficient due to low peptide concentration and rapid turnover
Solution Approach 1:
The patent transitions from conventional 1D detection methods to 2-D HPLE separation methodology, adding a dimensional aspect to the detection process. This two-dimensional approach enables resolution of peptides that co-migrate in traditional methods, thereby detecting low-concentration cancer-associated peptides that were previously undetectable
Solution Approach 2:
The patent uses PVDF membrane as an intermediary medium to capture and concentrate peptide fragments from complex biological fluids. The membrane acts as a mediator that selectively retains target peptides while allowing other components to pass through, thereby concentrating the low-abundance cancer peptides for subsequent detection
2Manufacturing precision
If existing separation methods are used, then separation capability is limited, but inability to distinguish serum albumin complexes prevents identification of useful biomarkers
Solution Approach 1:
The patent segments the complex serum protein mixture into distinct components using 2-D HPLE separation. This segmentation process resolves serum albumin complexes from other proteins and identifies specific peptide fragments bound to albumin, preventing loss of biomarker information that would occur with conventional separation methods
3Reliability
If biomarker detection is performed, then diagnostic capability is improved, but early intervention opportunity is lost if detection occurs only at late stages
Solution Approach 1:
The patent enables preliminary detection of cancer-associated peptides before clinical symptoms manifest. By detecting low-concentration peptides in early stage disease, the system allows preliminary diagnosis and intervention before the disease progresses to late stages, thereby preventing loss of intervention time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the detection of early stage cancer and potential therapeutic targeting by identifying elevated GASP-1 peptide levels in biological samples, providing a means for early intervention before cancer progresses to late stages, with a Competitive ELISA capable of detecting levels as low as 1 ng/mL.
Implementation Method 1
a modified 2-D High Performance Liquid Electrophoresis (2-D HPLE) method that separates albumin complexes on a PVDF membrane
Data Source
AI summary
A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.